Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Scribe Therapeutics Inc.

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in Upcoming Conferences
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Appoints Dr. Aarif Khakoo as Chief Scientific Officer and Head of Research and Development, and Dr. Maria Mirotsou as Vice President of Discovery Biology
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Presents Data on its X-Editing Technologies at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in Four Upcoming Conferences
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in Upcoming Investor Conferences
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics Expands Collaboration With Biogen to Second Target
From Scribe Therapeutics Inc.
Via Business Wire
Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference
From Scribe Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.